Aerie Pharmaceuticals

$23.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-0.46%) As of 1:52 PM EDT today
-$0.11 (-0.46%) Today

Why Robinhood?

You can buy or sell AERI and other stocks, options, ETFs, and crypto commission-free!

About AERI

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. Read More The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Employees
353
Headquarters
Durham, North Carolina
Founded
2005
Market Cap
1.10B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
921.52K
High Today
$24.38
Low Today
$23.50
Open Price
$23.88
Volume
284.43K
52 Week High
$64.25
52 Week Low
$20.72

Collections

AERI Earnings

-$1.73
-$1.41
-$1.10
-$0.78
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.